NexgenRx Inc.
NEGXF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3,017 | $4,346 | $4,551 | $3,939 |
| % Growth | -30.6% | -4.5% | 15.5% | – |
| Cost of Goods Sold | $775 | $785 | $927 | $567 |
| Gross Profit | $2,242 | $3,561 | $3,624 | $3,372 |
| % Margin | 74.3% | 81.9% | 79.6% | 85.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $209 | $219 | $44 |
| SG&A Expenses | $2,102 | $447 | $414 | $252 |
| Sales & Mktg Exp. | $0 | $238 | $196 | $208 |
| Other Operating Expenses | $0 | $2,775 | $2,660 | $2,654 |
| Operating Expenses | $2,102 | $3,222 | $3,074 | $2,906 |
| Operating Income | $140 | $339 | $550 | $465 |
| % Margin | 4.6% | 7.8% | 12.1% | 11.8% |
| Other Income/Exp. Net | $267 | -$8 | -$46 | -$12 |
| Pre-Tax Income | $407 | $331 | $504 | $453 |
| Tax Expense | -$16 | -$23 | -$23 | $481 |
| Net Income | $423 | $354 | $527 | -$28 |
| % Margin | 14% | 8.1% | 11.6% | -0.7% |
| EPS | 0.006 | 0.005 | 0.007 | -0 |
| % Growth | 12% | -28.6% | 1,850% | – |
| EPS Diluted | 0.006 | 0.005 | 0.006 | -0 |
| Weighted Avg Shares Out | 71,117 | 70,704 | 71,117 | 70,926 |
| Weighted Avg Shares Out Dil | 71,117 | 70,704 | 76,717 | 73,726 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $30 | $32 | $8 | $12 |
| Depreciation & Amortization | $225 | $323 | $314 | $316 |
| EBITDA | $662 | $661 | $826 | $744 |
| % Margin | 22% | 15.2% | 18.2% | 18.9% |